Dan Nomura

@[email protected]
660 Followers
447 Following
6 Posts
Professor of Chemical Biology and Molecular Therapeutics at the University of California, Berkeley; Departments of Chemistry and Molecular and Cell Biology; Director of the Novartis Translational Chemical Biology Institute; Co-Founder of Frontier Medicines; Founder of Vicinitas Therapeutics; Investment Advisory Board Member for Droia Ventures; www.nomuraresearchgroup.com
Research Group Websitewww.nomuraresearchgroup.com
Lab AddressInnovative Genomics Institute; 2151 Berkeley Way, Room 312G, Berkeley, CA 94720
Dan NomuraDec 20, 2022
Excited to showcase our latest work by @NafsikaForte and @UCB_Chemistry @berkeleyMCB & @NovartisScience on covalently recruiting E2 ubiquitin conjugating enzyme UBE2D for PROTAC and targeted protein degradation applications to degrade BRD4 and AR!! Also thanks to @TheMarkFdn! https://www.biorxiv.org/content/10.1101/2022.12.19.520812v1
Dan NomuraNov 18, 2022
Really excited to join Droia Ventures as an Investment Advisory Board member!! I've loved working with Droia on Frontier Medicines and Vicinitas Therapeutics and I'm looking forward to working with them on investing in next-generation life science companies!! https://droiaventures.com/#about
Droia Ventures – Investing in Impact – Life Science

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Droia Ventures – Investing in Impact
Dan NomuraNov 11, 2022
Hot new startup Lyterian Therapeutics from Michael Rape, Aaron Gitler, Ingrid Wertz, Robert Tjian, and Marius Wernig focused on drugging physiologically relevant protein homeostatic mechanisms! Congrats! https://lyterian.com
Lyterian Therapeutics

for treating disease

Lyterian Therapeutics
Dan NomuraNov 11, 2022
Cool paper from Merck chem bio team on chemoproteomic profiling to identify activity changes and functional inhibitors of DNA binding proteins. https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(22)00384-1#%20
Dan NomuraNov 7, 2022
Excited to present our BioRxiv preprint on chemical rational design strategies for developing molecular glue degraders through a covalent handle targeting RNF126! Congrats to Ethan Toriki and James Papatzimas and thanks to our Novartis collaborators! Also thanks to The Mark Foundation for Cancer Research! https://www.biorxiv.org/content/10.1101/2022.11.04.512693v1
Dan NomuraNov 7, 2022
I'm new to Mastodon! Still getting used to this new platform. I'm Dan Nomura, a Professor of Chemical Biology at UC Berkeley! My lab uses chemical biology approaches to tackle "undruggable" proteins and to develop new therapeutic modalities to develop next-generation disease therapies!